These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 21258118)
21. [A clinical experience of taurine and trimetazidine use in premenopausal women with chronic heart failure]. Sedova EM; Magnitskaia OV Kardiologiia; 2010; 50(1):62-3. PubMed ID: 20144159 [No Abstract] [Full Text] [Related]
22. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Lopaschuk GD; Barr R; Thomas PD; Dyck JR Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392 [TBL] [Abstract][Full Text] [Related]
23. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure. Dalal JJ; Mishra S Indian Heart J; 2017; 69(3):393-401. PubMed ID: 28648439 [TBL] [Abstract][Full Text] [Related]
24. [Possibilities of myocardial cytoprotection in complex treatment of patients with chronic heart failure]. Vasiuk IuA; Iushchuk EN; Shkol'nik EL; Khadzegova AB; Vit'ko NK; Vakhromeeva MN Kardiologiia; 2006; 46(11):48-56. PubMed ID: 17159882 [TBL] [Abstract][Full Text] [Related]
25. The metabolic treatment of coronary artery disease and heart failure. Di Napoli P Curr Pharm Des; 2009; 15(8):826. PubMed ID: 19275645 [No Abstract] [Full Text] [Related]
26. [Vasodilator agents in chronic heart failure: which is the best option?]. Corbalán R; Kunstmann S; Jalil J Rev Med Chil; 1993 Jan; 121(1):81-8. PubMed ID: 8235172 [TBL] [Abstract][Full Text] [Related]
27. Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease? Rizzon P; Iliceto S; Marangelli V Cardiologia; 1995 Oct; 40(10):717-20. PubMed ID: 8819732 [No Abstract] [Full Text] [Related]
28. Metabolic approach in heart failure: rethinking how we translate from theory to clinical practice. Tang WH J Am Coll Cardiol; 2006 Sep; 48(5):999-1000. PubMed ID: 16949493 [No Abstract] [Full Text] [Related]
29. Metabolic agents in the management of diabetic coronary patients: a new era. Celik T; Kursaklioglu H; Iyisoy A; Jata B Int J Cardiol; 2008 Jun; 127(1):133-4. PubMed ID: 17561287 [TBL] [Abstract][Full Text] [Related]
30. Role of trimetazidine in management of ischemic cardiomyopathy. Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202 [TBL] [Abstract][Full Text] [Related]
31. Clinical benefits of a metabolic approach with trimetazidine in revascularized patients with angina. Danchin N Am J Cardiol; 2006 Sep; 98(5A):8J-13J. PubMed ID: 16931200 [TBL] [Abstract][Full Text] [Related]
32. [Effects of trimetazidine on serum oxygen free radicals in congestive heart failure]. Ma QL; Xie Y; Zhang SD Hunan Yi Ke Da Xue Xue Bao; 2002 Dec; 27(6):527-9. PubMed ID: 12658930 [TBL] [Abstract][Full Text] [Related]
33. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Belardinelli R; Solenghi M; Volpe L; Purcaro A Eur Heart J; 2007 May; 28(9):1102-8. PubMed ID: 17456483 [TBL] [Abstract][Full Text] [Related]
34. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. Fragasso G; Palloshi A; Puccetti P; Silipigni C; Rossodivita A; Pala M; Calori G; Alfieri O; Margonato A J Am Coll Cardiol; 2006 Sep; 48(5):992-8. PubMed ID: 16949492 [TBL] [Abstract][Full Text] [Related]